サマリー

COX阻害剤は、主に解熱鎮痛消炎剤、すなわち非ステロイド系抗炎症剤（NSAIDs）である。COX-2は、正常な組織細胞では活性が極めて低く、誘導されて初めて大量に生産される。COX-2は、PGの合成を促進することで、痛みや炎症、発熱を媒介します。一般に、非ステロイド性抗炎症薬の複数の副作用は、COX-1の阻害に関連していると考えられています。その結果、COX-2選択的阻害剤が登場しました。

市場分析と洞察。世界と日本のシクロオキシゲナーゼ2阻害剤（COVID-19)市場
本レポートでは、世界と日本のシクロオキシゲナーゼ2阻害剤（COVID-19）市場に焦点を当てています。
2020年のシクロオキシゲナーゼ2阻害剤（COVID-19）の世界市場規模はXX百万米ドルで、2021-2027年の間にXX％のCAGRで、2027年末にはXX百万米ドルに達すると予想されています。日本では、シクロオキシゲナーゼ2阻害剤（COVID-19）の市場規模は、2020年のXX百万米ドルから2027年にはXX百万米ドルまで、予測期間中にXX％のCAGRで成長すると予測されています。

世界のシクロオキシゲナーゼ2阻害剤（COVID-19)範囲と市場規模
Cyclooxygenase 2 Inhibitor（COVID-19）の市場は、地域（国）別、プレイヤー別、タイプ別、アプリケーション別に分類されています。世界のシクロオキシゲナーゼ2阻害剤（COVID-19）市場のプレーヤー、ステークホルダー、その他の参加者は、本レポートを強力なリソースとして活用することで、優位に立つことができるでしょう。セグメント別分析では、地域（国）別、タイプ別、アプリケーション別に、2016年から2027年までの収益と予測に焦点を当てています。
日本市場では、2016-2027年のシクロオキシゲナーゼ2阻害剤（COVID-19）の市場規模を、プレイヤー別、タイプ別、アプリケーション別に分析しています。主要プレイヤーには、日本で重要な役割を果たしているグローバルプレイヤーとローカルプレイヤーが含まれています。

タイプ別セグメント
選択的Cox 2阻害剤
非選択的Cox 2阻害剤

用途別セグメント
病院
専門クリニック
その他

地域別
北アメリカ
アメリカ
カナダ
ヨーロッパ
ドイツ
フランス
イギリス
イタリア
ロシア
アジアパシフィック
中国
日本
韓国
インド
オーストラリア
台湾
インドネシア
タイ
マレーシア
フィリピン
ベトナム
ラテンアメリカ
メキシコ
ブラジル
アルゼンチン
中近東・アフリカ
トルコ
サウジアラビア
UAE

会社別
ファイザー
バイエル
ノバルティス
メルク
サビンサ
カディラ・ファーマシューティカルズ
マイラン
テバファーマ
アレンビックファーマ
オーロビンド・ファーマ
シプラ社
トレント・ファーマシューティカルズ

ページTOPに戻る

目次

1 Study Coverage
1.1 Cyclooxygenase 2 Inhibitor（COVID-19) Product Introduction
1.2 Market by Type
1.2.1 Global Cyclooxygenase 2 Inhibitor（COVID-19) Market Size Growth Rate by Type
1.2.2 Selective Cox 2 Inhibitor
1.2.3 Non-Selective Cox 2 Inhibitor
1.3 Market by Application
1.3.1 Global Cyclooxygenase 2 Inhibitor（COVID-19) Market Size Growth Rate by Application
1.3.2 Hospital
1.3.3 Specialty Clinic
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered

2 Executive Summary
2.1 Global Cyclooxygenase 2 Inhibitor（COVID-19) Market Size, Estimates and Forecasts
2.1.1 Global Cyclooxygenase 2 Inhibitor（COVID-19) Revenue 2016-2027
2.1.2 Global Cyclooxygenase 2 Inhibitor（COVID-19) Sales 2016-2027
2.2 Global Cyclooxygenase 2 Inhibitor（COVID-19), Market Size by Region: 2016 VS 2021 VS 2027
2.3 Cyclooxygenase 2 Inhibitor（COVID-19) Historical Market Size by Region (2016-2021)
2.3.1 Global Cyclooxygenase 2 Inhibitor（COVID-19) Retrospective Market Scenario in Sales by Region: 2016-2021
2.3.2 Global Cyclooxygenase 2 Inhibitor（COVID-19) Retrospective Market Scenario in Revenue by Region: 2016-2021
2.4 Cyclooxygenase 2 Inhibitor（COVID-19) Market Estimates and Projections by Region (2022-2027)
2.4.1 Global Cyclooxygenase 2 Inhibitor（COVID-19) Sales Forecast by Region (2022-2027)
2.4.2 Global Cyclooxygenase 2 Inhibitor（COVID-19) Revenue Forecast by Region (2022-2027)

3 Global Cyclooxygenase 2 Inhibitor（COVID-19) Competitor Landscape by Players
3.1 Global Top Cyclooxygenase 2 Inhibitor（COVID-19) Manufacturers by Sales
3.1.1 Global Cyclooxygenase 2 Inhibitor（COVID-19) Sales by Manufacturer (2016-2021)
3.1.2 Global Cyclooxygenase 2 Inhibitor（COVID-19) Sales Market Share by Manufacturer (2016-2021)
3.2 Global Top Cyclooxygenase 2 Inhibitor（COVID-19) Manufacturers by Revenue
3.2.1 Key Cyclooxygenase 2 Inhibitor（COVID-19) Manufacturers Covered: Ranking by Revenue
3.2.2 Global Cyclooxygenase 2 Inhibitor（COVID-19) Revenue by Manufacturers (2016-2021)
3.2.3 Global Cyclooxygenase 2 Inhibitor（COVID-19) Revenue Share by Manufacturers (2016-2021)
3.2.4 Global Cyclooxygenase 2 Inhibitor（COVID-19) Market Concentration Ratio (CR5 and HHI) (2016-2021)
3.2.5 Global Top 10 and Top 5 Companies by Cyclooxygenase 2 Inhibitor（COVID-19) Revenue in 2020
3.2.6 Global Cyclooxygenase 2 Inhibitor（COVID-19) Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Global Cyclooxygenase 2 Inhibitor（COVID-19) Price by Manufacturers
3.4 Global Cyclooxygenase 2 Inhibitor（COVID-19) Manufacturing Base Distribution, Product Types
3.4.1 Cyclooxygenase 2 Inhibitor（COVID-19) Manufacturers Manufacturing Base Distribution, Headquarters
3.4.2 Manufacturers Cyclooxygenase 2 Inhibitor（COVID-19) Product Type
3.4.3 Date of International Manufacturers Enter into Cyclooxygenase 2 Inhibitor（COVID-19) Market
3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Type (2016-2027)
4.1 Global Cyclooxygenase 2 Inhibitor（COVID-19) Market Size by Type (2016-2021)
4.1.1 Global Cyclooxygenase 2 Inhibitor（COVID-19) Sales by Type (2016-2021)
4.1.2 Global Cyclooxygenase 2 Inhibitor（COVID-19) Revenue by Type (2016-2021)
4.1.3 Cyclooxygenase 2 Inhibitor（COVID-19) Average Selling Price (ASP) by Type (2016-2021)
4.2 Global Cyclooxygenase 2 Inhibitor（COVID-19) Market Size Forecast by Type (2022-2027)
4.2.1 Global Cyclooxygenase 2 Inhibitor（COVID-19) Sales Forecast by Type (2022-2027)
4.2.2 Global Cyclooxygenase 2 Inhibitor（COVID-19) Revenue Forecast by Type (2022-2027)
4.2.3 Cyclooxygenase 2 Inhibitor（COVID-19) Average Selling Price (ASP) Forecast by Type (2022-2027)

5 Breakdown Data by Application (2016-2027)
5.1 Global Cyclooxygenase 2 Inhibitor（COVID-19) Market Size by Application (2016-2021)
5.1.1 Global Cyclooxygenase 2 Inhibitor（COVID-19) Sales by Application (2016-2021)
5.1.2 Global Cyclooxygenase 2 Inhibitor（COVID-19) Revenue by Application (2016-2021)
5.1.3 Cyclooxygenase 2 Inhibitor（COVID-19) Price by Application (2016-2021)
5.2 Cyclooxygenase 2 Inhibitor（COVID-19) Market Size Forecast by Application (2022-2027)
5.2.1 Global Cyclooxygenase 2 Inhibitor（COVID-19) Sales Forecast by Application (2022-2027)
5.2.2 Global Cyclooxygenase 2 Inhibitor（COVID-19) Revenue Forecast by Application (2022-2027)
5.2.3 Global Cyclooxygenase 2 Inhibitor（COVID-19) Price Forecast by Application (2022-2027)

6 Japan by Players, Type and Application
6.1 Japan Cyclooxygenase 2 Inhibitor（COVID-19) Market Size YoY Growth 2016-2027
6.1.1 Japan Cyclooxygenase 2 Inhibitor（COVID-19) Sales YoY Growth 2016-2027
6.1.2 Japan Cyclooxygenase 2 Inhibitor（COVID-19) Revenue YoY Growth 2016-2027
6.1.3 Japan Cyclooxygenase 2 Inhibitor（COVID-19) Market Share in Global Market 2016-2027
6.2 Japan Cyclooxygenase 2 Inhibitor（COVID-19) Market Size by Players (International and Local Players)
6.2.1 Japan Top Cyclooxygenase 2 Inhibitor（COVID-19) Players by Sales (2016-2021)
6.2.2 Japan Top Cyclooxygenase 2 Inhibitor（COVID-19) Players by Revenue (2016-2021)
6.3 Japan Cyclooxygenase 2 Inhibitor（COVID-19) Historic Market Review by Type (2016-2021)
6.3.1 Japan Cyclooxygenase 2 Inhibitor（COVID-19) Sales Market Share by Type (2016-2021)
6.3.2 Japan Cyclooxygenase 2 Inhibitor（COVID-19) Revenue Market Share by Type (2016-2021)
6.3.3 Japan Cyclooxygenase 2 Inhibitor（COVID-19) Price by Type (2016-2021)
6.4 Japan Cyclooxygenase 2 Inhibitor（COVID-19) Market Estimates and Forecasts by Type (2022-2027)
6.4.1 Japan Cyclooxygenase 2 Inhibitor（COVID-19) Sales Forecast by Type (2022-2027)
6.4.2 Japan Cyclooxygenase 2 Inhibitor（COVID-19) Revenue Forecast by Type (2022-2027)
6.4.3 Japan Cyclooxygenase 2 Inhibitor（COVID-19) Price Forecast by Type (2022-2027)
6.5 Japan Cyclooxygenase 2 Inhibitor（COVID-19) Historic Market Review by Application (2016-2021)
6.5.1 Japan Cyclooxygenase 2 Inhibitor（COVID-19) Sales Market Share by Application (2016-2021)
6.5.2 Japan Cyclooxygenase 2 Inhibitor（COVID-19) Revenue Market Share by Application (2016-2021)
6.5.3 Japan Cyclooxygenase 2 Inhibitor（COVID-19) Price by Application (2016-2021)
6.6 Japan Cyclooxygenase 2 Inhibitor（COVID-19) Market Estimates and Forecasts by Application (2022-2027)
6.6.1 Japan Cyclooxygenase 2 Inhibitor（COVID-19) Sales Forecast by Application (2022-2027)
6.6.2 Japan Cyclooxygenase 2 Inhibitor（COVID-19) Revenue Forecast by Application (2022-2027)
6.6.3 Japan Cyclooxygenase 2 Inhibitor（COVID-19) Price Forecast by Application (2022-2027)

7 North America
7.1 North America Cyclooxygenase 2 Inhibitor（COVID-19) Market Size YoY Growth 2016-2027
7.2 North America Cyclooxygenase 2 Inhibitor（COVID-19) Market Facts & Figures by Country
7.2.1 North America Cyclooxygenase 2 Inhibitor（COVID-19) Sales by Country (2016-2021)
7.2.2 North America Cyclooxygenase 2 Inhibitor（COVID-19) Revenue by Country (2016-2021)
7.2.3 U.S.
7.2.4 Canada

8 Asia Pacific
8.1 Asia Pacific Cyclooxygenase 2 Inhibitor（COVID-19) Market Size YoY Growth 2016-2027
8.2 Asia Pacific Cyclooxygenase 2 Inhibitor（COVID-19) Market Facts & Figures by Region
8.2.1 Asia Pacific Cyclooxygenase 2 Inhibitor（COVID-19) Sales by Region (2016-2021)
8.2.2 Asia Pacific Cyclooxygenase 2 Inhibitor（COVID-19) Revenue by Region (2016-2021)
8.2.3 China
8.2.4 Japan
8.2.5 South Korea
8.2.6 India
8.2.7 Australia
8.2.8 Australia
8.2.9 Indonesia
8.2.10 Thailand
8.2.11 Malaysia
8.2.12 Philippines
8.2.13 Vietnam

9 Europe
9.1 Europe Cyclooxygenase 2 Inhibitor（COVID-19) Market Size YoY Growth 2016-2027
9.2 Europe Cyclooxygenase 2 Inhibitor（COVID-19) Market Facts & Figures by Country
9.2.1 Europe Cyclooxygenase 2 Inhibitor（COVID-19) Sales by Country (2016-2021)
9.2.2 Europe Cyclooxygenase 2 Inhibitor（COVID-19) Revenue by Country (2016-2021)
9.2.3 Germany
9.2.4 France
9.2.5 U.K.
9.2.6 Italy

10 Latin America
10.1 Latin America Cyclooxygenase 2 Inhibitor（COVID-19) Market Size YoY Growth 2016-2027
10.2 Latin America Cyclooxygenase 2 Inhibitor（COVID-19) Market Facts & Figures by Country
10.2.1 Latin America Cyclooxygenase 2 Inhibitor（COVID-19) Sales by Country (2016-2021)
10.2.2 Latin America Cyclooxygenase 2 Inhibitor（COVID-19) Revenue by Country (2016-2021)
10.2.3 Mexico
10.2.4 Brazil
10.2.5 Argentina

11 Middle East and Africa
11.1 Middle East and Africa Cyclooxygenase 2 Inhibitor（COVID-19) Market Size YoY Growth 2016-2027
11.2 Middle East and Africa Cyclooxygenase 2 Inhibitor（COVID-19) Market Facts & Figures by Country
11.2.1 Middle East and Africa Cyclooxygenase 2 Inhibitor（COVID-19) Sales by Country (2016-2021)
11.2.2 Middle East and Africa Cyclooxygenase 2 Inhibitor（COVID-19) Revenue by Country (2016-2021)
11.2.3 Turkey
11.2.4 Saudi Arabia
11.2.5 UAE

12 Company Profiles
12.1 Pfizer
12.1.1 Pfizer Corporation Information
12.1.2 Pfizer Description and Business Overview
12.1.3 Pfizer Cyclooxygenase 2 Inhibitor（COVID-19) Sales, Revenue and Gross Margin (2016-2021)
12.1.4 Pfizer Cyclooxygenase 2 Inhibitor（COVID-19) Products Offered
12.1.5 Pfizer Recent Development
12.2 Bayer
12.2.1 Bayer Corporation Information
12.2.2 Bayer Description and Business Overview
12.2.3 Bayer Cyclooxygenase 2 Inhibitor（COVID-19) Sales, Revenue and Gross Margin (2016-2021)
12.2.4 Bayer Cyclooxygenase 2 Inhibitor（COVID-19) Products Offered
12.2.5 Bayer Recent Development
12.3 Novartis
12.3.1 Novartis Corporation Information
12.3.2 Novartis Description and Business Overview
12.3.3 Novartis Cyclooxygenase 2 Inhibitor（COVID-19) Sales, Revenue and Gross Margin (2016-2021)
12.3.4 Novartis Cyclooxygenase 2 Inhibitor（COVID-19) Products Offered
12.3.5 Novartis Recent Development
12.4 Merck
12.4.1 Merck Corporation Information
12.4.2 Merck Description and Business Overview
12.4.3 Merck Cyclooxygenase 2 Inhibitor（COVID-19) Sales, Revenue and Gross Margin (2016-2021)
12.4.4 Merck Cyclooxygenase 2 Inhibitor（COVID-19) Products Offered
12.4.5 Merck Recent Development
12.5 Sabinsa
12.5.1 Sabinsa Corporation Information
12.5.2 Sabinsa Description and Business Overview
12.5.3 Sabinsa Cyclooxygenase 2 Inhibitor（COVID-19) Sales, Revenue and Gross Margin (2016-2021)
12.5.4 Sabinsa Cyclooxygenase 2 Inhibitor（COVID-19) Products Offered
12.5.5 Sabinsa Recent Development
12.6 Cadila Pharmaceuticals
12.6.1 Cadila Pharmaceuticals Corporation Information
12.6.2 Cadila Pharmaceuticals Description and Business Overview
12.6.3 Cadila Pharmaceuticals Cyclooxygenase 2 Inhibitor（COVID-19) Sales, Revenue and Gross Margin (2016-2021)
12.6.4 Cadila Pharmaceuticals Cyclooxygenase 2 Inhibitor（COVID-19) Products Offered
12.6.5 Cadila Pharmaceuticals Recent Development
12.7 Mylan
12.7.1 Mylan Corporation Information
12.7.2 Mylan Description and Business Overview
12.7.3 Mylan Cyclooxygenase 2 Inhibitor（COVID-19) Sales, Revenue and Gross Margin (2016-2021)
12.7.4 Mylan Cyclooxygenase 2 Inhibitor（COVID-19) Products Offered
12.7.5 Mylan Recent Development
12.8 Teva Pharmaceutical
12.8.1 Teva Pharmaceutical Corporation Information
12.8.2 Teva Pharmaceutical Description and Business Overview
12.8.3 Teva Pharmaceutical Cyclooxygenase 2 Inhibitor（COVID-19) Sales, Revenue and Gross Margin (2016-2021)
12.8.4 Teva Pharmaceutical Cyclooxygenase 2 Inhibitor（COVID-19) Products Offered
12.8.5 Teva Pharmaceutical Recent Development
12.9 Alembic Pharmaceutical
12.9.1 Alembic Pharmaceutical Corporation Information
12.9.2 Alembic Pharmaceutical Description and Business Overview
12.9.3 Alembic Pharmaceutical Cyclooxygenase 2 Inhibitor（COVID-19) Sales, Revenue and Gross Margin (2016-2021)
12.9.4 Alembic Pharmaceutical Cyclooxygenase 2 Inhibitor（COVID-19) Products Offered
12.9.5 Alembic Pharmaceutical Recent Development
12.10 Aurobindo Pharma
12.10.1 Aurobindo Pharma Corporation Information
12.10.2 Aurobindo Pharma Description and Business Overview
12.10.3 Aurobindo Pharma Cyclooxygenase 2 Inhibitor（COVID-19) Sales, Revenue and Gross Margin (2016-2021)
12.10.4 Aurobindo Pharma Cyclooxygenase 2 Inhibitor（COVID-19) Products Offered
12.10.5 Aurobindo Pharma Recent Development
12.11 Pfizer
12.11.1 Pfizer Corporation Information
12.11.2 Pfizer Description and Business Overview
12.11.3 Pfizer Cyclooxygenase 2 Inhibitor（COVID-19) Sales, Revenue and Gross Margin (2016-2021)
12.11.4 Pfizer Cyclooxygenase 2 Inhibitor（COVID-19) Products Offered
12.11.5 Pfizer Recent Development
12.12 Torrent Pharmaceuticals
12.12.1 Torrent Pharmaceuticals Corporation Information
12.12.2 Torrent Pharmaceuticals Description and Business Overview
12.12.3 Torrent Pharmaceuticals Cyclooxygenase 2 Inhibitor（COVID-19) Sales, Revenue and Gross Margin (2016-2021)
12.12.4 Torrent Pharmaceuticals Products Offered
12.12.5 Torrent Pharmaceuticals Recent Development

13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
13.1 Cyclooxygenase 2 Inhibitor（COVID-19) Industry Trends
13.2 Cyclooxygenase 2 Inhibitor（COVID-19) Market Drivers
13.3 Cyclooxygenase 2 Inhibitor（COVID-19) Market Challenges
13.4 Cyclooxygenase 2 Inhibitor（COVID-19) Market Restraints

14 Value Chain and Sales Channels Analysis
14.1 Value Chain Analysis
14.2 Cyclooxygenase 2 Inhibitor（COVID-19) Customers
14.3 Sales Channels Analysis
14.3.1 Sales Channels
14.3.2 Distributors

15 Research Findings and Conclusion

16 Appendix
16.1 Research Methodology
16.1.1 Methodology/Research Approach
16.1.2 Data Source
16.2 Author Details
16.3 Disclaimer